BRUSSELS (REUTERS) - Europe's drug regulator said on Thursday (March 11) it had initiated a rolling review of United States-based Eli Lilly's antibodies to treat Covid-19, days after saying their combination could be used in patients at high risk of progressing to severe illness.

Lilly's bamlanivimab and etesemivab belong to a class of drugs called monoclonal antibody treatments, which mimic natural antibodies the body generates to fight infection.